Items
141 ~ 160 of 26060, Page 8 of 1303 |
141. Explore Your Family Cancer History |
Protect your health by learning more about your family¡¯s history of cancer and other health problems. Then find out what you can do to help lower your risk. Get the tips. |
06/13/2019
American Cancer Society |
|
|
|
|
145. Population of US Cancer Survivors Grows to Nearly 17 Million |
A new report by the American Cancer Society ? in collaboration with the National Cancer Institute ? estimates there are more than 16.9 million cancer survivors alive in the US today, and that number will grow to more than 22.1 million by 2030. |
06/11/2019
American Cancer Society |
|
146. FDA Approves Two New Indications for Merck¡¯s KEYTRUDA¢ç (pembrolizumab) |
KEYTRUDA Now Approved for First-Line Treatment of Patients with Metastatic or with Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma as Monotherapy for Patients Whose Tumors Express PD-L1 (CPS ¡Ã1) or in Combination with Platinum and Fluorouracil (FU) Regardless of PD-L1 Expression |
06/11/2019
MERCK |
|
|
|
|
150. Mental and Physical Health Drive Employee Productivity |
Mental and physical health are the most important factors affecting workplace productivity, reports an open-access paper in the June Journal of Occupational and Environmental Medicine. |
06/10/2019
American College of Occupational and Environmental Medicine (ACOEM) |
|
|
|
|
|
|
|
|
|
|
160. New Research from Merck¡¯s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting |
First-Time Data from POLO Trial Evaluating LYNPARZA ¢ç (olaparib) in Germline BRCA-Mutated Metastatic Pancreatic Cancer in Plenary Session and ASCO Press Program / KEYTRUDA ¢ç (pembrolizumab) Five-Year Survival Data in Advanced Non-Small Cell Lung Cancer (NSCLC) from KEYNOTE-001 Trial in ASCO Press Program / Overall Survival Data for KEYTRUDA in Metastatic Renal Cell Carcinoma (RCC), Recurrent/Metastatic Head and Neck Cancer and Advanced Gastric or Gastroesophageal Junction (GEJ) Cancer |
05/15/2019
MERCK |
|